FAM
ECYT

Fred Alger Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Fred Alger Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,000
Closed -$41K – 594
2018
Q2 		$41K Buy
+3,000
New +$35.6K ﹤0.01% 430

Other funds holding ECYT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fred Alger Management's ECYT Position: Q3 2018 in Review

Fred Alger Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 3,000 shares — an estimated $41K sold.

Fred Alger Management first reported a position in ECYT in Q2 2018 and held it in 1 quarter. The position peaked at $41K in Q2 2018. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

  • Fred Alger Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Fred Alger Management sold 3,000 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $41K.
  • Fred Alger Management first reported a position in Endocyte, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Fred Alger Management's Endocyte, Inc. Common Stock position peaked at $41K in Q2 2018.
  • 139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Fred Alger Management's 13F filing for Q3 2018, filed 14 Nov 2018.